LYRA
Lyra Therapeutics, Inc. (LYRA) SWOT Analysis Analysis (2026)
Strengths
Current ratio and quick ratio of 1.71 indicate near-term liquidity is adequate, which compares better than distressed peers despite weak profitability.
Cash conversion cycle of 0 suggests working-capital discipline, supporting cash preservation relative to peers with longer inventory and receivables cycles.
Weaknesses
ROIC of -70.6% shows capital is being destroyed at a severe rate, leaving LYRA structurally behind profitable peers on value creation.
Negative net debt to EBITDA and debt-to-equity metrics indicate the capital structure is not meaningfully supported by earnings, unlike stronger peer balance sheets.
Missing positive operating and gross margin data, combined with weak returns, implies the business lacks durable pricing power versus peers.
Liquidity is only adequate rather than strong, so the company remains more vulnerable than peers if operating losses persist.
Opportunities
If management improves unit economics, the current liquidity cushion could support a turnaround more effectively than peers with tighter balance sheets.
A zero cash conversion cycle provides a base for incremental efficiency gains, which could narrow the gap versus peers with weaker working-capital execution.
Threats
Persistent negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest faster and widen structural advantages.
Weak profitability increases financing risk, making LYRA more exposed than peers if capital markets tighten or losses continue.
Absent evidence of diversified earnings streams, the company appears more vulnerable than peers to demand softness and margin compression.
Overall Score
LYRA’s structural positioning versus peers is weak because severe value destruction and limited profitability outweigh only modest liquidity and working-capital support.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lyra Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

